ALLO News and Press, Allogene Therapeutics Inc. From 07/15/22

Allogene Therapeutics ( NASDAQ: ALLO ) stock rose ~9% premarket July 15 after Goldman Sachs upgrade the stock to Buy from Neutral with a price target of $32, from $9. The SA Quant Rating on ALLO is Hold , which takes into account factors such as growth and prof...

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D....

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Allogene's leadership position in allogeneic CAR-T can be rewarding for early investors. However, being a pioneer has its pitfalls. The company has a decent amount of cash. For further details see: Allogene Therapeutics: Multibagger Potential, But Terribly Risky

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this event. For further details see: Allogene Therapeutics (ALLO) Investor Presentation (Slideshow)

Allogene Therapeutics (NASDAQ:ALLO) on Wednesday said that the U.S. FDA had granted a regenerative medicine advanced therapy (RMAT) designation to its investigational product ALLO-501A for the treatment of large B-cell lymphoma, a type of cancer in white blood cells called lymphocyt...

RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of Hematology (ASH) 2021 Annual Meeting Demonstrated AlloCAR T™ Could be Safe and Ef...

Gainers: Repare Therapeutics  (RPTX) +20%. Credo Technology Group Holding  (CRDO) +8%. Elevation Oncology (ELEV) +8%. MongoDB (MDB) +6%. Global Blood Therapeutics (GBT) +5%. Losers: Charge Enterprises (CRGE) -5%. NerdWallet (NRDS) -5%. Protagonist Therapeutics (PTGX) -5%. ...

Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with Cancer Findings Underscore Potential of Allogeneic CAR T Products to Improve Patient Outcomes SOUTH SAN FRANCISCO, Calif., May ...

Gene editing biotech, Caribou Biosciences (NASDAQ:CRBU) has recorded the best intraday gain on Thursday after releasing Phase 1 data for its allogeneic anti-CD19 CAR-T cell therapy, CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma. Noting the favorable early results, SVB Leerink h...